Retatrutide + Cagrilintide: Two Investigational Drugs, No Combination Data
Also known as: Retatrutide + Cagrilintide · Reta + Cagri · Retatrutide/Cagrilintide blend
This pairs two investigational drugs that have never been trialled together and are not developed by the same company. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist in late-stage trials. Cagrilintide is a long-acting amylin analog, studied in combination with semaglutide as CagriSema — not with retatrutide. So while the mechanistic idea (incretin plus amylin) has support from the CagriSema programme, that support belongs to a different pairing. There is no dosing data, no safety data, and no efficacy data for this combination. Educational only, not medical advice.
The mechanistic argument, and its limits
Amylin and incretin pathways are genuinely complementary. Amylin slows gastric emptying and signals satiety through a different receptor system than GLP-1, which is the rationale behind combining an amylin analog with an incretin drug. The CagriSema programme — cagrilintide plus semaglutide — is the real-world test of that idea and has produced substantial phase-3 weight-loss results.
The gap is that CagriSema pairs cagrilintide with semaglutide, a single GLP-1 agonist. Retatrutide is a triple agonist hitting GIP, GLP-1 *and* glucagon receptors, and on its own it has produced the largest weight-loss figures of any incretin drug in trials so far. Stacking an amylin analog on top of an already-triple-agonist is a different proposition, not an extension of the CagriSema result.
Neither the additive benefit nor the additive side-effect burden has been measured.
Why "no data" matters more here
With most blends on this page the components are widely used and their individual profiles are reasonably characterised. That is not the case here — both compounds are still investigational. Retatrutide is not approved anywhere. Cagrilintide is not approved as a standalone.
The dose-limiting problem with this drug class is gastrointestinal — nausea and vomiting are the most common reasons people stop, and they are dose-dependent. Combining two compounds that both slow gastric emptying and both suppress appetite means the tolerability question is not theoretical. In the CagriSema trials, GI adverse events were a meaningful part of the picture even with a well-characterised pairing and a controlled titration schedule.
Rapid weight loss also carries a lean-mass cost that is proportionally normal but absolute-magnitude large when the total loss is large. That is a real consideration with the most potent compounds in this class, and it is one worth planning protein and resistance training around rather than discovering afterwards.
How to track Retatrutide + Cagrilintide in Stackeddd
If you run anything in this class, weight alone is the wrong metric — it cannot distinguish fat from lean mass, and lean loss is the known cost of fast weight loss. Log weight, waist and a strength benchmark together so you can see which one is moving.
Model it yourself · free, no account
Blood-Level Simulator
Model the components separately: when a blend mixes a short-acting compound with a long one, the chart shows why a single injection interval cannot suit both.
Related compounds
Related reading: Semaglutide vs Tirzepatide: half-life, cadence, and what to track · Injection frequency: daily vs EOD vs weekly
Frequently asked questions
Has retatrutide been studied with cagrilintide?
No. Cagrilintide has been studied in combination with semaglutide, as CagriSema, which is a different pairing from a different manufacturer. There are no published trials of retatrutide combined with cagrilintide — no dosing, safety or efficacy data for that combination.
Why would anyone combine an amylin analog with an incretin drug?
Because amylin signals satiety and slows gastric emptying through a different receptor system than GLP-1, so the pathways are complementary rather than redundant. The CagriSema programme is the real test of that idea and has produced strong phase-3 results — but with semaglutide, not with a triple agonist.
What is the main risk of stacking these?
Tolerability. Gastrointestinal side effects are the dose-limiting problem for this whole class and are the most common reason people discontinue. Combining two compounds that both slow gastric emptying and suppress appetite compounds that burden, and nobody has measured how much.
This is educational information, not medical advice. Doses and protocols above reflect published references and community practice — protocol decisions belong with your prescribing physician. Generic names used throughout. How this reference is built & how the AI is tested →
STACKEDDD
Track it instead of guessing.
Doses, reconstitution, bloodwork, and an AI coach grounded in your own data — free to start, on the App Store and Google Play.